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Introduction
Pulmonary function measures refl ect the normal and pathological state of the lungs. The most commonly used measures are the forced expiratory volume in 1 s (FEV 1 ) and the ratio of FEV 1 to forced vital capacity (FEV 1 /FVC). These measurements are integral to th e diagnosis of chronic obstructive pulmonary disease (COPD), and are also important long-term predictors of population morbidity and all-cause mortality. 1 Pulmonary function is determined by both environmental and genetic factors. Tobacco smoking is the major environmental risk factor for reduced pulmonary function. The genetic contribution to pulmonary function is well established, with estimates of heritability for FEV 1 as high as 50%. 2, 3 The SpiroMeta consortium and the Consortium of Heart and Aging Research in Genomic Epidemiology (CHARGE) have published several genome-wide association studies (GWAS) that identifi ed 26 loci associated with FEV 1 and FEV 1 /FVC in the general population. [4] [5] [6] Although these fi ndings provide new insights into the genetic architecture of lung function, the exact genes and biological mechanisms underlying these associations remain largely unclear. Single nucleotide polymorphisms (SNPs) can determine phenotypic traits by altering the quantity or function of the mRNA or protein for which the gene codes, or both. 7 Recent studies suggest that for complex traits, SNPs in regulatory regions that control the level of gene expression are overrepresented in GWAS fi ndings compared with coding variants. 8, 9 Genetic loci that control gene expression are called expression quantitative trait loci (eQTLs) and can be identifi ed by testing SNPs for association with mRNA or protein expression. 10 Gene regulation is often tissuespecifi c, 11, 12 and hence to make meaningful discoveries of eQTLs for lung function and COPD, it is informative to study the genetic control of lung-specifi c gene expression. The lung eQTL consortium identifi ed 468 300 cis-acting (aff ecting expression of genes within 1 Mb of the transcript start site) and 16 677 trans-acting (further than 1 Mb away or on a diff erent chromosome) eQTLs out of 2 598 263 SNPs at a 10% false discovery rate (FDR) in a large-scale eQTL mapping study of 1111 human lung tissues. [13] [14] [15] [16] [17] Systems genetics enables a global analysis of molecular mechanisms by integrating data for genetic variation with intermediate phenotypes such as gene expression (mRNA, protein or both), epigenetics changes, or metabolite levels and examining how they interact and converge to alter complex traits and diseases. [18] [19] [20] [21] [22] We hypothesised that a subset of SNPs identifi ed in the SpiroMeta-CHARGE GWAS meta-analysis of about 48 000 individuals 5 aff ect variation in lung function by acting as eQTLs to change the level of expression of their target genes in the lung. In this study, a systems genetics approach was used to overlap results from the SpiroMeta-CHARGE GWAS meta-analysis with the lung eQTLs identifi ed by the lung eQTL consortium and to leverage the SNP-mRNA-lung function correlations to unravel genes and molecular mechanisms underlying lung function variation.
Methods

Study design
The overall study design is shown in fi gure 1. The fi rst step was the identifi cation of lung function eSNPs: SNPs with an association p value (p GWAS ) <0·001 that act as cis or trans lung eQTLs at an FDR of less than 10%. This step formed the basis for all downstream analyses. At the SNP level, the enrichment of SpiroMeta-CHARGE GWAS hits for lung eQTLs was calculated, and the expected direction of association of mRNA with lung function was inferred given the SNP associations with lung function and mRNA. eSNPs were additionally assessed for functional annotations in the Encyclopedia of DNA Elements (ENCODE) dataset, and for evidence of pleiotropy in the National Human Genome Research Institute (NHGRI) human GWAS Catalog. At the gene level, lung function eSNP-regulated genes in lung tissue were tested for enrichment in pathways and gene ontology processes. Then the pathways were compared with lung functionrelated genes regulated by eSNPs in blood. The potential developmental role of lung function genes was tested by comparison with a study of the transcriptome in human fetal lung. The levels of expression of lung function genes in lung tissue were tested for association with lung function measures and COPD in participants from the eQTL study. Finally, the Connectivity Map (CMap) database was used to identify potential therapeutics in silico for COPD using the disease's gene expression signature in lung tissue.
Study cohorts
The methods and participant characteristics of the SpiroMeta-CHARGE lung function GWAS have been described in detail elsewhere. 5 Briefl y, meta-analyses for cross-sectional lung function measures were undertaken for approximately 2·5 million HapMap II imputed SNPs
Research in context
Evidence before this study We searched PubMed for reports published in English before Nov 1, 2014. We used the search terms "genome-wide association" and "eQTL" and "lung function" or "FEV 1 " or "FEV 1 /FVC" or "COPD". We additionally searched the published genome-wide association study (GWAS) catalogue. At the time of our search, no large-scale integration reports of GWAS and lung expression quantitative trait loci (eQTLs) existed for lung function measures or chronic obstructive pulmonary disease (COPD). Evidence from GWAS in other diseases suggests that integration of GWAS results with eQTLs in relevant tissue can identify the genes most likely to be responsible for the associations and unravel the molecular mechanisms underlying variation in lung function.
Added value of this study
We show to our knowledge for the fi rst time that single nucleotide polymorphisms (SNPs) associated with lung function are enriched for lung eQTLs. This study identifi ed a large number of SNPs/genes that determine the variation in lung function measures; these were enriched in developmental and infl ammatory pathways. Lung function genes are supported by evidence from GWAS, eQTL, and mRNA associations with lung function and as such represent potential therapeutic and biomarker targets. Furthermore, we used the resulting lung gene expression signature to identify potential novel COPD drugs with an in-silico drug repositioning approach.
Implications of all the available evidence Our study has identifi ed genes underlying the variation in lung function in lung tissue, representing testable hypotheses for future in-vitro and in-vivo studies. Our results serve as a unique resource to the larger scientifi c community interested in the pathogenesis and genetics of obstructive lung diseases.
across 23 individual GWAS with a combined sample size of 48 201 adult individuals of European ancestry. The analyses of FEV 1 and FEV 1 /FVC were adjusted for age, age 2 , sex, and height, and where appropriate study centre and ancestry principal components as covariates.
The methods and participant characteristics of the lung tissue eQTL study have been described in detail elsewhere. 13 Briefl y, lung eQTLs were derived from a meta-analysis of non-tumour lung tissue eQTLs from 1111 patients who underwent lung resection surgery at three participating sites: the University of British Columbia Centre for Heart and Lung Innovation (Vancouver, Canada; n=339), Laval University (Quebec City, Canada; n=409) and the University of Groningen (Groningen, Netherlands; n=363). The expression data are available at NCBI Gene Expression Omnibus repository (accession number GSE23546). Genotyping was performed on DNA extracted from blood or lung tissue with the Illumina Human1M-Duo BeadChip array, and imputation was performed using the HapMap II reference panel providing eQTL data for 2 598 263 million SNPs. With a Benjamini-Hochberg 10% FDR threshold, the study identifi ed 468 300 cis (18% of all SNPs tested) and 16 677 trans eQTLs representing 0·64% of all SNPs tested.
Appropriate ethics approval for the lung function GWAS and the lung eQTL studies was received from all participating institutions.
Analyses and statistical analyses
To integrate the SNPs that were associated with FEV 1 or FEV 1 /FVC, or both, with gene expression in the lung, we fi rst merged the 468 300 cis-eQTLs and the 16 677 transeQTLs with SNPs in the SpiroMeta and CHARGE GWAS (2 419 122 SNPs at N eff ective >50%). Merged SNPs were then fi ltered to select those with a p GWAS <0·001 for association with FEV 1 or FEV 1 /FVC. Throughout this report we refer to SNPs associated with FEV 1 or FEV 1 /FVC that act as eQTLs as lung function eSNPs, and the genes regulated by these SNPs as lung function eSNP-regulated genes. Fold enrichments were calculated from the merged results and signifi cance of the enrichment of eSNPs among SpiroMeta-CHARGE GWAS results was ca culated by Fisher's exact test.
The lung function eSNP-regulated genes were tested for enrichment in gene ontology biological processes and pathways with the Web-based Gene Set Analysis Toolkit (WebGestalt). 23 For lung function eSNP-regulated genes, the relation between mRNA expression levels and lung function measures was examined in 727 of the 1111 participants in the lung eQTL study. The subset of participants who were selected had the appropriate measures of lung function and did not have a diagnosis (other than COPD or lung cancer) likely to aff ect lung function. Table 1 shows the demographics of this subgroup of participants. A linear regression analysis of the level of expression of each probe set on FEV 1 and FEV 1 /FVC, adjusted for age, sex, height, and smoking status was done for each of three cohorts separately, followed by meta-analysis.
The allelic eff ect of the eSNPs on FEV 1 and FEV 1 /FVC from the GWAS, and on mRNA from the lung eQTL study was used to infer the predicted direction of eff ect between the mRNA and lung function measures; we refer to this as the expected direction. Independently, we regressed the mRNA levels of lung function eSNPregulated genes on FEV 1 and FEV 1 /FVC in the subset of 727 participants of the eQTL study, and we refer to the direction of eff ect for this association as the observed direction. For lung function eSNP-regulated probe sets that show signifi cant mRNA association with lung function measures, we investigated whether the observed direction of eff ect was either concordant or discordant with the expected direction.
To identify potential compounds that could reverse (or induce) COPD-associated genes, the Connectivity Map online tool from the Broad Institute was used. 24 The Connectivity Map hosts a publically available database of transcriptional profi les produced by existing drugs. Lung function eSNPs were defi ned as GWAS SNPs with p GWAS <0·001 that act as cis or trans lung eQTLs passing the 10% FDR. The enrichment of SpiroMeta-CHARGE GWAS for eSNPs was calculated. The expected direction of eff ect of mRNA on lung function was inferred. Lung function eSNP-regulated genes in lung tissue were tested for pathway and gene ontology processes enrichment, and the pathways were compared with blood lung function eSNP-regulated genes. The level of expression of lung function eSNP-regulated genes was tested for association with lung function measures in participants from the eQTL study. The lung function eSNPs and their target genes were tested for ENCODE functional enrichment and for transcription factor enrichment in the promoters of lung function eSNP-regulated genes. Furthermore, lung function eSNPs were integrated with the National Human Genome Research Institute human GWAS Catalog, to identify pleiotropic associations. The potential developmental role of lung function eSNP-regulated genes was tested by comparison with a study of the transcriptome of human fetal lung. Finally, the expression pattern of eSNP-regulated genes that were associated with COPD was interrogated using the Connectivity Map database to identify potential therapeutics in silico. eQTLs=expression quantitative trait loci. FDR=false discovery rate. GWAS=genome-wide association studies. SNP=single nucleotide polymorphisms. The database contains more than 7000 genome-wide transcriptomes from cultured human cells treated with 1309 bioactive compounds. Since the Connectivity Map expects a gene signature of upregulated and downregulated genes as input, we tested the expression levels of lung function eSNP-regulated genes for diff erential expression between COPD cases (n=428) and controls (n=330) in individuals from the eQTL study. 51 lung function eSNP-regulated genes associated with COPD at nominal p values of <0·05 were mapped into Aff ymetrix platform HG-U133A probe set IDs (33 genes were remapped) to be used as input for the Connectivity Map to query compounds that could reverse or augment the airway obstruction gene signature.
Lung function eSNPs were tested for pleiotropy (a SNP that infl uences multiple diseases/traits) by integrating them with the NHGRI GWAS Catalog. 25 The ENCODE ChIP-Seq Signifi cance Tool 26 was used to gain insights into what transcription factors were enriched in the promoters of lung function eSNP-regulated genes. At the SNP level, lung function eSNPs were tested for enrichment in ENCODE functional annotations with HaploReg v2 publically available software. 27 We assessed whether SpiroMeta-CHARGE SNPs with p GWAS <0·001 act as cis-eQTLs meeting 10% FDR in nontransformed peripheral blood mononuclear cells (PBMCs) obtained from 5311 European participants. 28 An eQTL was defi ned as cis-acting if the SNP position is less than 250 Kb away from the midpoint of the probe.
All statistical analyses were done with R version 3.0.1. Additional and detailed methods are available in the appendix (pp 3-6).
Role of the funding source
The funding sources had no roles in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Of the 2 419 122 SNPs investigated in the SpiroMeta-CHARGE GWAS, 440 665 were cis-eQTLs, and 15 135 were trans-eQTLs that passed the 10% FDR in the lung eQTL study. Figure 2 shows a quantile-quantile (Q-Q) plot of the SpiroMeta-CHARGE associations with FEV 1 and FEV 1 /FVC for the cis-eQTLs and trans-eQTLs. The y axis represents the quantiles of the eQTLs' associations with FEV 1 or FEV 1 /FVC in the SpiroMeta-CHARGE GWAS, plotted against an expected distribution derived from the GWAS p values for all 2 419 122 SNPs. The plots show a large systematic deviation of p values for eQTLs compared with the GWAS association p values for all SNPs. Table 2 shows that of the 440 665 cis-eQTLs, 3413 were associated with FEV 1 and 2205 were associated with FEV 1 /FVC in the SpiroMeta-CHARGE GWAS study at p GWAS <0·001. Of the 15 135 trans-eQTLs, 1568 were associated with FEV 1 (38-fold enrichment) and 442 with FEV 1 /FVC (12·6-fold enrichment) at p GWAS <0·001. We refer to these eQTLs as lung function eSNPs. The enrichment is stronger for trans-eQTLs, possibly because of the more stringent statistical threshold needed to defi ne a trans-eQTL. Enrichments at diff erent p GWAS cutoff s are shown in the appendix (pp [25] [26] . The deviation in the Q-Q plots and the enrichment in table 2 suggest that lung eQTLs are enriched for associations with lung function in the SpiroMeta-CHARGE GWAS, and vice versa. That a SNP is associated with both a lung function phenotype and with lung gene expression increases the likelihood that it is involved in a causal pathway, 10 especially since most SNPs identifi ed in GWAS do not aff ect protein coding.
To validate these fi ndings, lung eQTLs were overlapped with results from a GWAS meta-analysis for type 2 diabetes from Morris and colleagues. 29 The meta-analysis consisted of 12 171 cases of type 2 diabetes and 56 862 controls across 12 GWAS from European descent populations. Similar analyses to the lung function GWAS overlap were done to obtain Q-Q plots for blood and lung type 2 diabetes eSNPs (appendix p 7). The Q-Q plot shows that the enrichment for lung function SNPs in lung tissue eQTLs is systematically diff erent compared with that for type 2 diabetes.
Since baseline enrichment could be expected for GWAS SNPs proximal to genes irrespective of being eQTLs in the relevant tissue, a comparison was made of SpiroMeta-CHARGE SNPs within 1 Mb of known genes to all SNPs. The Q-Q plots (appendix p 8) show a modest deviation for proximal SNPs but only for SNPs with low p GWAS . However, the deviation is less than what is seen in the Q-Q plots of lung eSNPs (fi gure 2), suggesting that genomic distance alone does not explain the deviation noted for lung eSNPs and that this large deviation is driven by the tissue type used for eQTL discovery and its relevance to the phenotype under investigation.
The full list of lung function cis and trans eSNPregulated genes is provided in the appendix (pp 27-68). A Venn diagram illustrating the extent of overlap for cis and trans FEV 1 and FEV 1 /FVC eSNP-regulated genes is shown in the appendix (p 9). For example, there are 63 lung function cis eSNP-regulated genes associated with both FEV 1 and FEV 1 /FVC. Table 3 shows lung eQTL integration results for 50 SNPs within the 26 loci reported in three of the consortia's published meta-analyses that met the genome-wide signifi cance threshold. [4] [5] [6] Of the 50 lung functionassociated SNPs reported in the three meta-analyses, 25 (50%) act as lung eSNPs at 10% FDR. Table 3 shows the GWAS p values and the genes suggested to underlie the associations in the published reports (usually the closest gene), as well as the lung eQTL-regulated genes and the eQTL p values for the SNPs. For ten of the 25 eSNPs, the GWAS-suggested gene (based on SNP position) and the eSNP-regulated gene were the same. Another ten of the 25 eSNP-regulated genes were diff erent from the ones suggested in the GWAS. For four of the 25, the eSNP regulated the expression of more than one gene, including the gene suggested by the GWAS. In these instances, the level of eQTL statistical signifi cance with the alternative genes was usually stronger. Finally, one eSNP (rs2857595) regulated the expression of 11 genes, which did not include the GWAS suggested gene-NCR3 in this case. 5 Some of the reported SNPs reside at the same locus and are in linkage disequilibrium.
The pathway analyses of lung function cis eSNPregulated genes identifi ed several enriched gene ontology processes that were common for FEV 1 and FEV 1 /FVC (fi gure 3). These processes were related to development and infl ammatory or immune responses such as natural killer T-cell diff erentiation, immune system processes, and positive regulation of the immune system. No gene ontology processes were signifi cantly enriched (at any FDR value) among the 29 FEV 1 and 21 FEV 1 /FVC trans-regulated genes. Cis and trans lung function eSNP-regulated genes were enriched for several Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (appendix p 10 and p 23).
To test whether the genes and pathways identifi ed by integration of the GWAS and lung eQTL data were unique to lung tissue, we compared the results with those derived from integration of the SpiroMeta-CHARGE GWAS SNPs that had p GWAS <0·001 with ciseQTL data derived from non-transformed PBMCs reported in a study of 5311 participants. 28 Similar to lung function eSNP-regulated genes derived from the lung tissue analysis, lung function eSNP-regulated genes derived from blood were enriched in processes related to development, maturation, and infl ammatory processes (appendix p 13). To extend the analysis, we performed gene ontology process enrichment analyses on genes from three groups: lung-only regulated genes, bloodonly regulated genes, and shared lung and blood regulated genes. The results (appendix p 84) showed that lung function eSNP-regulated genes restricted to blood were enriched solely for infl ammatory processes, whereas eSNPregulated genes in lung tissue and those shared between lung and blood were enriched for both developmental and infl ammatory processes. In con cordance with these results, lung function eSNP-regulated genes were over-represented among genes diff erentially expressed during human fetal lung development (appendix pp 86-116).
There were 868 unique lung function eSNP-regulated probe sets when overlap between FEV 1 and FEV 1 The table reports lung eQTL results for genome-wide associated SNPs (listed by locus) in the three published FEV 1 and FEV 1 /FVC consortia manuscripts. [4] [5] [6] Gene names shown in parentheses are previous gene symbols or synonyms. FEV 1 =forced expiratory volume in 1 s. FEV 1 /FVC=ratio of FEV 1 to forced vital capacity. GWAS=genome-wide association studies. SNP=single nucleotide polymorphisms. ··=SNP is not a lung eQTL at the 10% FDR. *Denotes the GWAS p value from the meta-analysis of discovery and replication stages. †Denotes that the SNP achieved genome-wide signifi cance in the discovery cohort only in the CHARGE study. ‡SNP rs2070600 was also reported in the CHARGE study 6 (p=3·15 × 10 -¹⁴ for association with FEV 1 /FVC). eQTLs=expression quantitative trait loci. ⁰⁶, and as such they did not meet the GWAS cutoff for signifi cance at p<5 × 10 -⁸). Furthermore, the Q-Q plots (appendix p 14) show a systematic deviation of lung function eSNPregulated probe set associations with FEV 1 and FEV 1 /FVC compared with the expected distribution under the null hypothesis of no association. This fi nding is expected in view of how these genes were identifi ed; by GWAS and lung eQTL analyses, and the deviation supports the integrative approach for fi nding genes that underlie the phenotype. For 56% of the lung function eSNP-regulated probe sets, the direction of eff ect in the eQTL participants was concordant with the expected fi nding. The concordance at diff erent p GWAS cutoff s remained modest (appendix p 146).
The identifi cation of eSNPs helps unravel interesting biological relations, such as the signifi cant interaction detected on lung function between eSNPs for the receptor encoding gene PTCH1 and its ligand competitor encoding HHIP (appendix p 24). Additionally, eSNPs in the HHIP locus were in high linkage disequilibrium with two functional SNPs identifi ed in vitro by Zhou and colleagues 30 to regulate the expression of HHIP (appendix pp 147-148). Furthermore, lung eSNPs in the 4q31 (HHIP) and 15q25 (CHRNA3/5) loci were also recently identifi ed by Castaldi and colleagues as COPD eSNPs in blood and sputum tissues (appendix p 149). 31 The appendix (p 15) shows a Circos plot 32 to summarise results from the multiple associations for lung function eSNPs: the GWAS p values, lung eQTL p values, and the p values for the lung mRNA associations with FEV 1 and FEV 1 /FVC in the lung eQTL study.
Lung function eSNPs were associated at GWAS Catalog p values ranging from 9 × 10 -⁶ to 4 × 10 -¹⁸⁶ with several diseases and traits (appendix pp 150-204) that can be broadly classifi ed into four categories: (1) infl ammatory (including asthma, ulcerative colitis, type 1 diabetes, leprosy, C reactive protein levels); (2) developmental (including age at menopause, bone mineral density, age at onset of menarche, height, and primary tooth development); (3) neuropsychiatric (including schizophrenia, autism, Parkinson's disease, bipolar disorder, nicotine dependence, smoking behaviour); and (4) cardiovascular and obesity-related traits.
By use of ChIP-Seq data from the ENCODE project, lung function eSNP-regulated genes were seen to be To gain insights and generate hypotheses about potential therapeutic agents for COPD, the mRNA levels of lung function eSNP-regulated genes were tested for association with COPD in individuals from the eQTL study (appendix pp 209-233). The resulting COPD gene signature was then used to query the Connectivity Map database of drug gene expression profi les to identify potential COPD therapeutics. Several agents had a negative enrichment score suggesting that they are predicted to reverse the COPD gene signature. These agents included the local anaesthetic and non-selective nicotinic receptor blocker adiphenine; disulfi ram, which is used as a treatment for alcohol dependence and as a possible treatment for cocaine dependence; perphenazine, a dopamine D1 and D2 receptor antagonist; GABAA receptor antagonists (SR-95531; Gabazine), and anti-infl ammatory and antioxidant agents (hecogenin and withaferin A). Among the agents that had a positive enrichment score (ie, predicted to induce COPD) were vorinostat and trichostatin A, both of which act as histone deacetylase inhibitors; alsterpaullone, a cyclin-dependent kinase inhibitor; and the chemotherapeutic agent doxorubicin (appendix pp 234-235).
Discussion
Studies of genetic associations and examination of gene expression in relevant tissues are important steps in unravelling the molecular mechanisms underlying common diseases. In this study, a systems genetics approach was used to integrate the largest published GWAS on the two major lung function parameters used clinically-FEV 1 and FEV 1 /FVC-with a powerful lung tissue eQTL resource. The main fi ndings are that lung function associated SNPs are enriched for lung eQTLs and vice versa; integration identifi es the specifi c genes that are more likely to be responsible for the GWAS signal; lung function eSNP-regulated genes in lung tissue are involved in developmental and infl ammatory pathways whereas lung function eSNP-regulated genes in PBMCs are associated only with infl ammatory pathways; and the importance of developmental pathways is emphasised by the strong overrepresentation of lung function eSNP-regulated genes among genes that are diff erentially expressed during fetal lung development. Additionally, we noted that the associations of mRNA levels of lung function eSNP-regulated genes with lung function showed stronger associations to what is expected by chance in individuals from the lung eQTL study, and in-silico analysis showed that several compounds are predicted to reverse (nicotine receptor antagonists) or to induce (histone deacetylase inhibitors) the COPD gene signature and could guide discovery of new therapeutics.
Restricting susceptibility loci to those that achieve genome-wide signifi cance in GWAS is recognised as overly conservative; however, including SNPs with higher p values will identify false-positive associations unless there is additional evidence to implicate these variants. 33 We chose to interrogate all SNPs with p GWAS <0·001, because this threshold might uncover biologically relevant yet statistically modest associations. The usefulness of this approach is suggested by the fact that 47% of the SNPs associated with FEV 1 and 42% of the SNPs associated with FEV 1 /FVC were cis-acting or trans-acting eSNPs. This fi nding represents substantial enrichment since only 18% and 0·6% of all SNPs acted as cis and trans lung eQTLs, respectively.
The discovery of eSNPs could help to identify genes in causal pathways, especially in regions containing multiple genes. For example, intronic SNP rs10516526 in GSTCD on chromosome 4q24, which showed one of the strongest associations with FEV 1 (p=4·75 × 10 -¹⁴) maps to a linkage disequilibrium rich region containing the GSTCD, INTS12, and NPNT genes. In lung tissue, rs10516526 is an eQTL for NPNT but not for GSTCD or INTS12. However, in PBMCs 28 and lymphoblastoid cell lines, 15 the same SNP is an eQTL for INTS12, refl ecting the tissue specifi city of eQTLs. These results suggest that one mechanism through which this susceptibility locus could have its eff ect is through modulation of the lung tissue levels of NPNT, a conclusion strengthened by the association between FEV 1 /FVC and mRNA levels for NPNT in the lung eQTL participants (p=0·01) and by the strong NPNT staining of pulmonary endothelial cells and alveolar epithelial cells (appendix p 21).
The identifi cation of trans-eSNPs in particular reveals novel genes that would not be implicated because of their genomic position. An example is the retinol binding protein (RBP2; appendix p 23). Alternatively, integration of GWAS and eQTL results provides additional support for commonly associated genes. For example, the intergenic SNP rs13141641 on 4q31, which showed one of the strongest GWAS associations with FEV 1 /FVC (p=8·451 × 10 -¹⁸) is a lung (but not blood) eQTL for HHIP. HHIP eSNPs identifi ed in this study were in strong linkage disequilibrium with functional SNPs reported by Zhou and colleagues 30 to aff ect the expression of HHIP in vitro (appendix pp 147-148).
HHIP blocks the hedgehog signalling pathway by binding to PTCH1 ligands, a membrane receptor for the hedgehog (HH) proteins, Sonic (SHH), Desert (DHH), and Indian hedgehog (IHH). Interestingly, a SNP (rs10512248) in PTCH1 was associated with FEV 1 /FVC (p=9·2 × 10 -⁰⁵) and is an eQTL for PTCH1 (p=1·1 × 10 -⁰⁵). The availability of eQTL data thus allows the suggestion of a biologically plausible causal pathway for the PTCH1/HHIP combination of susceptibility alleles. The HHIP allele that is associated with lower lung function substantially increases the mRNA levels of HHIP, suggesting that decreased hedgehog signalling adversely aff ects lung development. Similarly, the PTCH1 allele that is associated with lower lung function substantially decreases the expression of the receptor, which would also be expected to decrease hedgehog signalling. There was a strong interaction between the HHIP and PTCH1 eSNPs on FEV 1 and FEV 1 /FVC in the participants of the eQTL study (appendix p 22 and p 24). The availability of mRNA data from the lung tissue samples of the participants of the eQTL study provides additional support for this pathway; higher levels of HHIP (p=0·01 for FEV 1 and p=0·003 for FEV 1 /FVC) and lower levels of PTCH1 (p=0·004 for FEV 1 and p=0·0006 for FEV 1 /FVC) were associated with worse lung function in this cohort. Lung function eSNPregulated genes derived from analysis of lung tissue, and to a lesser extent, lung function eSNP-regulated genes derived from the analysis of PBMCs were enriched for genes involved in development, maturation, and infl ammatory processes. Lung function eSNP-regulated genes that were unique only to blood cells were enriched for infl ammatory but not developmental processes. A link between lung development and growth in utero or in infancy and impaired lung function and COPD in adults has been previously proposed, [34] [35] [36] [37] [38] [39] and indeed genes determining adult lung function have also been associated with reduced airway calibre in early childhood. 40 The molecular mechanisms explaining this link remain poorly understood. Lung function eSNPregulated genes such as TGFB2, HHIP, PTCH1, NOTCH4, and RBP2 are members of families that are well known for their role in lung development and growth. 34, [41] [42] [43] [44] [45] [46] [47] [48] [49] Additional support for the role of developmental genes as determinants of lung function is the fi nding that lung function eSNP-regulated genes were enriched among genes that vary in expression during human fetal lung development.
Infl ammation was the other enriched pathway. Infl ammation is inextricably linked to tissue remodelling and repair processes, which can aff ect the lung parenchyma and airways to alter lung function. 50 Although infl ammation and lung development could operate independently of each other, it is also feasible that the two processes interact. Infl ammation may lead to activation of tissue repair and remodelling processes that reactivate genes involved in lung development and growth. Alternatively, genetically determined variation in lung development and growth could alter lung structure to aff ect particle deposition and the infl ammatory response to toxic inhalants, such as tobacco smoke.
In this study, gene expression could be related to lung function in the same participants whose lung tissue was used to generate the lung eQTL data. The mRNA expression of 193 probe sets (22% of all probe sets tested) showed signifi cant association with either FEV 1 or FEV 1 /FVC at a nominal p value. This level of association is more than would be expected by chance as shown in the Q-Q plot. Of the 193 probe sets, 109 (56%) showed an observed direction of eff ect that was concordant with the expected direction of eff ect. There are several potential mechanisms that could explain discordant relations for the other 84 probe sets (44%). First, changes in gene expression may be a response to the disease process and the magnitude of this response may overwhelm the eff ect of the eSNP. Second, although the expected direction is based on the eff ect of the top eSNP for that gene, the same gene could also be under genetic control of other weaker eSNPs that collectively have an opposite direction of eff ect. Third, epigenetic modifi cations or microRNAs could also aff ect the levels of expression. Finally, the relation could simply be a false-positive fi nding, in view of our relaxed nominal p values threshold.
The identifi cation of genes that underlie lung function variation in lung tissue could be an essential step for COPD drug and biomarker development. In-silico drug repositioning can identify existing drugs that recapitulate or reverse the gene signature associated with COPD. Such screening has proven to be a valuable method for drug repurposing. [51] [52] [53] The Connectivity Map data suggest that vorinostat and trichostatin A, both of which act as histone deacetylase inhibitors, can reproduce the COPD gene signature. Histone deacetylase activators such as theophylline have been suggested as a treatment for COPD, especially in combination with corticosteroids. 54 Trichostatin A has also been shown to cause emphysema in rats, and was associated with decreased vascular endothelial growth factor (VEGF) expression. 55 Another Connectivity Map candidate inducer of COPD, alsterpaullone, downregulates VEGF and fi broblast growth factor. 56 Connectivity Map analysis showed several compounds that reversed the COPD gene signature, including adiphenine, a local anaesthetic that nonselectively inhibits at least four diff erent nicotinic acetylcholine receptor (nAChR) subtypes. 57, 58 SNPs at the 15q25 locus containing genes encoding the nAChRs CHRNA3 and CHRNA5 have been associated with lung cancer, COPD, and lung function. [59] [60] [61] [62] nAChR in the lung has been reported to have a role in cell proliferation and apoptosis in response to carcinogens, 63, 64 as well as in infl ammation. 65 Other compounds that reverse the COPD gene signature aff ect dopamine; these include disulfi ram, which is used as a treatment for alcohol dependence and is being explored for use in cocaine dependence. 66 Disulfi ram inhibits dopamine β-hydroxylase, which converts dopamine to norepinephrine. 66 Perphenazine is an antagonist of dopamine D1 and D2 receptors, 67 which also binds to the α-adrenergic receptor. 68 One study suggested that dopamine receptor and transporter genes (DRD2 and SLC6A3) might have a role in the progression of COPD. 69 To our knowledge, this study is the fi rst to report largescale integration of lung function GWAS and lung eQTLs. The datasets used are the largest so far and the results represent a resource to the scientifi c community as a whole. The availability of lung tissue mRNA levels, eQTLs, and lung function measures on the same individuals provided a unique complementary resource to lung function GWAS fi ndings, and aids the translation of SNP associations into actionable targets.
Our study has some limitations. First, such large-scale integration of GWAS and eQTLs can lead to coincidental overlap that is not necessarily refl ective of disease biology. Recent methods have been proposed to integrate GWAS and eQTLs such as colocalisation, 70 a weighted approach, 71 and signature matching. 72 Additionally, as the number of respiratory-related tissue eQTLs increases, approaches employing joint analysis of eQTLs in multiple tissues 73 will be needed to increase power. Second, although the eQTL discovery and mRNA associations were adjusted for smoking status, this adjustment could have undermined the power to detect SNPs and mRNAs that show markedly diff erent associations in smokers versus non-smokers (interaction). Additionally, no adjustments for pack-years were made. Projects that investigate these relations represent future avenues to follow up fi ndings from this study. Finally, the Connectivity Map drug gene expression profi les were measured in non-respiratory cancer cell lines, which could be diff erent from lung or airway-related expression profi les. Similar drug repurposing approaches in respiratory-related cells or tissues are warranted.
In summary, the systems genetics approach identifi ed genes and molecular mechanisms that underlie the variation in lung function measures, generating hypotheses for future in-vitro and in-vivo studies. This study emphasises the importance of lung development and infl ammatory pathways for lung function variation in adults. The fi nding that existing drugs can reverse the lung tissue gene signature associated with airfl ow obstruction suggests attractive candidates for interfering with the pathogenesis of COPD.
